Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,447,106 | $1,062,161 | $300,379 | $713,336 |
| - Cash | $110,552 | $91,542 | $25,976 | $247,790 |
| + Debt | $2,593,139 | $2,750,523 | $2,845,135 | $2,876,056 |
| Enterprise Value | $4,929,693 | $3,721,142 | $3,119,538 | $3,341,602 |
| Revenue | $2,793,957 | $2,393,607 | $2,212,304 | $2,093,669 |
| % Growth | 16.7% | 8.2% | 5.7% | – |
| Gross Profit | $1,020,438 | $863,869 | $791,461 | $768,973 |
| % Margin | 36.5% | 36.1% | 35.8% | 36.7% |
| EBITDA | $439,773 | $500,782 | $440,208 | $401,097 |
| % Margin | 15.7% | 20.9% | 19.9% | 19.2% |
| Net Income | -$116,886 | -$83,993 | -$129,986 | $10,624 |
| % Margin | -4.2% | -3.5% | -5.9% | 0.5% |
| EPS Diluted | -0.38 | -0.48 | -0.86 | 0.07 |
| % Growth | 20.8% | 44.2% | -1,328.6% | – |
| Operating Cash Flow | $295,099 | $345,577 | $65,100 | $241,820 |
| Capital Expenditures | -$74,990 | -$69,189 | -$90,595 | -$47,728 |
| Free Cash Flow | $220,109 | $276,388 | -$25,495 | $194,092 |